Personalized combo therapy aims to outsmart aggressive lymphoma

NCT ID NCT06803693

Recruiting now Disease control Sponsor: Ruijin Hospital Source: ClinicalTrials.gov ↗

First seen Jan 04, 2026 · Last updated May 14, 2026 · Updated 24 times

Summary

This study tests whether adding targeted drugs based on a patient's genetic profile to standard chemotherapy (Pola-RCHP) works better than standard chemo alone for people with untreated diffuse large B-cell lymphoma. About 152 adults aged 18-75 with intermediate-to-high risk disease will participate. The goal is to see if the personalized approach improves how long patients live without their cancer returning.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Ruijin Hospital, Shanghai JiaoTong University School of Medicine
RECRUITING

Shanghai, Shanghai Municipality, 200025, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

DIFFUSE LARGE B-CELL LYMPHOMA